These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 7225487)

  • 1. Plasma free and total tryptophan, blood serotonin, and the hyperactivity syndrome: no evidence for the serotonin deficiency hypothesis.
    Ferguson HB; Pappas BA; Trites RL; Peters DA; Taub H
    Biol Psychiatry; 1981 Mar; 16(3):231-8. PubMed ID: 7225487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of methylphenidate on the sympathoadrenal reactivity in children diagnosed as hyperactive.
    Nagel-Hiemke M; Berg B; Reinhardt D; Karch D; Pothmann R
    Klin Padiatr; 1984; 196(2):78-82. PubMed ID: 6737952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diminished serotonergic functioning in hostile children with ADHD: tryptophan depletion increases behavioural inhibition.
    Zepf FD; Holtmann M; Stadler C; Demisch L; Schmitt M; Wöckel L; Poustka F
    Pharmacopsychiatry; 2008 Mar; 41(2):60-5. PubMed ID: 18311686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tryptophan metabolism in children with attentional deficit disorder.
    Irwin M; Belendiuk K; McCloskey K; Freedman DX
    Am J Psychiatry; 1981 Aug; 138(8):1082-5. PubMed ID: 7258386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The diagnostic evaluation and therapeutic basis of immediate release methylphenidate in attention deficit hyperactivity disorder].
    Valdizán JR
    Rev Neurol; 2004 Mar 16-31; 38(6):501-6. PubMed ID: 15054710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet serotonin concentration in children with attention-deficit/hyperactivity disorder.
    Hercigonja Novkovic V; Rudan V; Pivac N; Nedic G; Muck-Seler D
    Neuropsychobiology; 2009; 59(1):17-22. PubMed ID: 19221444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. School observations of children with attention-deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment.
    Gadow KD; Nolan E; Sprafkin J; Sverd J
    J Dev Behav Pediatr; 1995 Jun; 16(3):167-76. PubMed ID: 7560119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder.
    Nikles CJ; Mitchell GK; Del Mar CB; Clavarino A; McNairn N
    Pediatrics; 2006 Jun; 117(6):2040-6. PubMed ID: 16740846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures.
    Posey DJ; Aman MG; McCracken JT; Scahill L; Tierney E; Arnold LE; Vitiello B; Chuang SZ; Davies M; Ramadan Y; Witwer AN; Swiezy NB; Cronin P; Shah B; Carroll DH; Young C; Wheeler C; McDougle CJ
    Biol Psychiatry; 2007 Feb; 61(4):538-44. PubMed ID: 17276750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematologic and blood biochemistry monitoring during methylphenidate treatment in children with attention-deficit/hyperactivity disorder: 2-year, open-label study results.
    Wigal SB; Wilens TE; Wolraich M; Lerner M
    Pediatrics; 2007 Jul; 120(1):e120-8. PubMed ID: 17548486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial.
    Akhondzadeh S; Tavakolian R; Davari-Ashtiani R; Arabgol F; Amini H
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):841-5. PubMed ID: 12921918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age and medication effects on rhythmic responses in ADHD: possible oscillatory mechanisms?
    Ben-Pazi H; Shalev RS; Gross-Tsur V; Bergman H
    Neuropsychologia; 2006; 44(3):412-6. PubMed ID: 16083921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder.
    Bilici M; Yildirim F; Kandil S; Bekaroğlu M; Yildirmiş S; Değer O; Ulgen M; Yildiran A; Aksu H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):181-90. PubMed ID: 14687872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood serotonin and tryptophan in Tourette syndrome.
    Comings DE
    Am J Med Genet; 1990 Aug; 36(4):418-30. PubMed ID: 2389798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attentional capacity, a probe ERP study: differences between children with attention-deficit hyperactivity disorder and normal control children and effects of methylphenidate.
    Jonkman LM; Kemner C; Verbaten MN; Van Engeland H; Camfferman G; Buitelaar JK; Koelega HS
    Psychophysiology; 2000 May; 37(3):334-46. PubMed ID: 10860411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: a double blind, randomized clinical trial.
    Amiri S; Mohammadi MR; Mohammadi M; Nouroozinejad GH; Kahbazi M; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):145-9. PubMed ID: 17765380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The course of behaviour changes in children with attention deficit and hyperactivity after drug treatment].
    Roselló B; Pitarch I; Abad L
    Rev Neurol; 2002 Feb; 34 Suppl 1():S82-90. PubMed ID: 12447796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.